Coughlin Timothy 4

What Happened

• Timothy Coughlin, a director of aTYR PHARMA INC (ATYR), was granted a derivative award of 50,000 shares on May 11, 2026. The Form 4 shows the acquisition price as $0.00 and reports a value of $0 on the filing; the award is described in the filing as an option granted under the company’s non-employee director compensation policy. This was an award (not a sale or open-market purchase) and no shares were sold.

Key Details

• Transaction date: May 11, 2026; Form 4 filed May 13, 2026 (timely filing).
• Reported transaction: Grant / Award (derivative) — 50,000 shares @ $0.00 (reported value $0).
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Footnote: The option vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer’s 2027 Annual Meeting of Stockholders, subject to Coughlin’s continued board service.
• No indication in the filing that shares were immediately exercised or sold.

Context

• This is a standard director compensation award under aTYR’s policy; such grants are routine for non-employee directors and do not necessarily reflect immediate buying or selling sentiment. Because this is a derivative option award that vests in the future, any potential economic interest depends on vesting and any exercise price (not specified in the excerpt).